Ceresney, Focusing on Pharma, Discusses SEC Enforcement Priorities and Compliance Expectations

Andrew Ceresney, the SEC’s Director of Enforcement, recently reaffirmed the SEC’s emphasis on cooperation and self-reporting and highlighted three pharmaceutical company practices that have led to FCPA enforcement actions.  Speaking at CBI’s Pharmaceutical Compliance Congress in Washington, D.C., Ceresney, like others before him, emphasized the benefits of self-reporting.  See also “Top FCPA Officials Talk Compliance Tips and the Defense Bar Weighs In,” The FCPA Report, Vol. 3, No. 25 (Dec. 17, 2014).

To read the full article

Continue reading your article with an ACR subscription.